

CONTINUED FROM PAGE 166

Conclusion

The use of BoNT products for both on- and off-label cosmetic and medical indications has rapidly grown over the past 2 decades. As demonstrated in this review, a variety of promising new products and delivery techniques are being developed. Given the rise in popularity of BoNT products among both physicians and consumers, clinicians should be aware of the current data and ongoing research.

REFERENCES

- Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. *J Dermatol Surg Oncol.* 1992;18:17-21.
- American Society for Aesthetic Plastic Surgery. Cosmetic Surgery National Data Bank statistics. American Society for Aesthetic Plastic Surgery website. <http://www.surgery.org/sites/default/files/ASAPS-Stats2015.pdf>. Accessed June 12, 2016.
- Walker TJ, Dayan SH. Comparison and overview of currently available neurotoxins. *J Clin Aesthet Dermatol.* 2014;7:31-39.
- Feng Z, Sun Q, He L, et al. Optimal dosage of botulinum toxin type A for treatment of glabellar frown lines: efficacy and safety in a clinical trial. *Dermatol Surg.* 2015; 41(suppl 1):S56-S63.
- Jiang HY, Chen S, Zhou J, et al. Diffusion of two botulinum toxins type A on the forehead: double-blinded, randomized, controlled study. *Dermatol Surg.* 2014; 40:184-192.
- Garcia-Murray E, Velasco Villasenor ML, Acevedo B, et al. Safety and efficacy of RT002, an injectable botulinum toxin type A, for treating glabellar lines: results of a phase 1/2, open-label, sequential dose-escalation study. *Dermatol Surg.* 2015;41(suppl 1):S47-S55.
- Won CH, Kim HK, Kim BL, et al. Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study. *Int J Dermatol.* 2015;54:227-234.
- Kim BJ, Kwon HH, Park SY, et al. Double-blind, randomized non-inferiority trial of a novel botulinum toxin A processed from the strain CBFC26, compared with onabotulinumtoxin A in the treatment of glabellar lines. *J Eur Acad Dermatol Venereol.* 2014;28:1761-1767.
- Kim JE, Song EJ, Choi GS, et al. The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines. *Plast Reconstr Surg.* 2015;135:732-741.
- Alam M, Bolotin D, Carruthers J, et al. Consensus statement regarding storage and reuse of previously reconstituted neuromodulators. *Dermatol Surg.* 2015;41:321-326.
- Alam M, Geisler A, Sadhwani D, et al. Effect of needle size on pain perception in patients treated with botulinum toxin type A injections: a randomized clinical trial. *JAMA Dermatol.* 2015;151:1194-1199.
- Pucks N, Thomas A, Hallam MJ, et al. Cutaneous cooling to manage botulinum toxin injection-associated pain in patients with facial palsy: a randomised controlled trial. *J Plast Reconstr Aesthet Surg.* 2015;68:1701-1705.
- Kranz G, Sycha T, Voller B, et al. Pain sensation during intradermal injections of three different botulinum toxin preparations in different doses and dilutions. *Dermatol Surg.* 2006;32:866-890.
- Lowe PL, Lowe WJ. Botulinum toxin type B: pH change reduces injection pain, retains efficacy. *Dermatol Surg.* 2014;40:1328-1333.
- Mahmoud BH, Burnett C, Ozog D. Prospective randomized controlled study to determine the effect of topical application of botulinum toxin A for crow's feet after treatment with ablative fractional CO₂ laser. *Dermatol Surg.* 2015;41(suppl 1):S75-S81.
- Montaser-Kouhsari L, Zartab H, Fanian F, et al. Comparison of intradermal injection with iontophoresis of abobotulinum toxin A for the treatment of primary axillary hyperhidrosis: a randomized, controlled trial. *J Dermatolog Treat.* 2014;25:337-341.
- Iannitti T, Palmieri B, Aspiro A, et al. A preliminary study of painless and effective transdermal botulinum toxin A delivery by jet nebulization for treatment of primary hyperhidrosis. *Drug Des Devel Ther.* 2014;8:931-935.
- Iozzo I, Tengattini V, Antonucci VA. Multipoint and multilevel injection technique of botulinum toxin A in facial aesthetics. *J Cosmet Dermatol.* 2014;13:135-142.
- Sneath J, Humphrey S, Carruthers A, et al. Injecting botulinum toxin at different depths is not effective for the correction of eyebrow asymmetry. *Dermatol Surg.* 2015;41(suppl 1):S82-S87.
- Steinsapir KD, Rootman D, Wulc A, et al. Cosmetic microdroplet botulinum toxin A forehead lift: a new treatment paradigm. *Ophthal Plast Reconstr Surg.* 2015;31:263-268.